41 results on '"Jalan R"'
Search Results
2. PWE-115 Acute decompensation of cirrhosis requiring hospitalisation is not reversible and defines future organ specific decompensation
3. PWE-098 Increase in gut permeability is an early event in cirrhosis and is not associated with bacterial translocation, systemic inflammation or clinical features: a prospective longitudinal study
4. PWE-094 Monitoring heart rate variability during acute decompensation predicts mortality and risk of recurrent hospitalisation
5. PTH-095 Oral carbon therapy is associated with a selective modulation of the microbiome in cirrhotic rats which is associated with a significant reduction in inflammatory activation
6. PWE-141 Alfa pump for the treatment of refractory ascites: a “real world” experience from the uk
7. PWE-099 Porto-systemic shunt embolization and recurrent ascites: a single centre case series
8. OC-035 Lifetouch®: A Novel Remote Monitoring Device To Identify Patients With Advanced Cirrhosis Most At Risk Of Decompensation – A Proof Of Concept Study
9. RETROSPECTIVE REVIEW OF INJECTION THERAPY IN MORTON'S NEUROMA
10. PMO-091 TLR 9 inhibition: a novel target of therapy for primary liver cancer
11. PWE-267 Urinary TLR4: a novel biomarker to identify patients with acute kidney injury in patients with acute on chronic liver failure: Abstract PWE-267 Figure 1
12. PTU-016 Albumin restores renal blood flow (RBF) autoregulation in patients with refractory ascites and acute-on-chronic liver failure (ACLF) through stabilisation of endothelial function: Abstract PTU-016 Figure 1
13. PWE-264 Blood lipidomic profiling of hepatocellular carcinoma in human and animal studies identifies lysophosphatidylcholine (24, 0, 0), a discriminatory biomarker
14. PMO-092 TLR7 expression is increased in hepatocellular cancer (HCC) and its modulation is associated with alterations in tumour growth: a novel therapeutic target
15. PWE-265 Plasma metabolite profiling in a rat model of hepatocellular carcinoma and the effects of co-administered antibiotics
16. PTU-008 A reproducible, clinically-relevant, intensively-managed, pig model of acute liver failure for testing of therapies aimed to prolong survival
17. PMO-128 Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis
18. PMO-123 Gene transfer of dimethylarginine dimethylaminohydrolase-1 reduces portal pressure in a rodent model of cirrhosis
19. PMO-142 Evidence refuting the Trojan-horse hypothesis of brain swelling in acute liver failure: l-type glutaminase is exclusively neuronal: Abstract PMO-142 Figure 1
20. OC-066 Toll like receptor 4 antagonist prevents acetaminophen induced acute liver failure in mice: a novel therapeutic strategy
21. OC-023 Extracorporeal liver support using UCL-arsenel reduces inflammation, improves haemodynamic function and increase survival time in a porcine paracetamol-induced acute liver failure model
22. PTU-049 Modulation of toll-like receptor genes with selective gut decontamination in cirrhotic animals prevents the development of acute-on chronic liver failure (ACLF)
23. PTU-030 Selective gut decomtamination reduces hepatic expression of toll-like receptor (TLR) 4 and development of cirrhosis but does not prevent development of hepatocellular carcinoma (HCC)
24. OC-068 Albumin is central in mediating the cardio-renal dysfunction of cirrhosis: a study in analbuminaemic rats: Abstract OC-068 Figure 1
25. PTU-010 Computational model predicts that portosystemic shunting is key to the development of hyperammonaemia in liver cirrhosis
26. PMO-127 Biological effects of oral nanoporous carbon in bile duct ligated rats
27. OP09 TIPS outcomes for refractory ascites: a single centre experience
28. P17 TIPS outcomes for Budd-Chiari: a single tertiary centre experience
29. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis
30. Acute-on-chronic liver failure: an early biopsy is essential?
31. Management of gastric fundal varices associated with a gastrorenal shunt Reply
32. PROSPECTS FOR EXTRACORPOREAL LIVER SUPPORT
33. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver
34. Losartan and renal sodium handling Reply
35. UK guidelines on the management of variceal haemorrhage in cirrhotic patients
36. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure
37. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis
38. TIPSS 10 years on
39. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?
40. Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients.
41. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.